Investor Overview

Webcast ImageWebcast
Verastem Inc at the 18th Annual BIO CEO & Investor Conference (Live)
02/09/16 at 8:00 a.m. ET
Verastem Inc at the 18th Annual BIO CEO & Investor Conference
Tuesday, February 9, 2016 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Verastem Inc at the Leerink Partners 5th Annual Global Healthcare Conference (Live)
02/10/16 at 11:30 a.m. ET
Verastem Inc at the Leerink Partners 5th Annual Global Healthcare Conference
Wednesday, February 10, 2016 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK and PI3K/mTOR.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.13
Change (%) Stock is Down 0.06 (5.04%)
Volume252,584
Data as of 02/05/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
01/27/16Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jan. 27, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: 18th Annual BIO CEO & Investor Conference on Tuesday, February 9 at 8:00 a.m. ET at the Waldorf Astoria Hotel in New York City Leerink Partners 5th Annual Global Healthcare Conferen... 
Printer Friendly Version
01/21/16Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
BOSTON--(BUSINESS WIRE)--Jan. 21, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held January 25-27, 2016 in Washington, DC. “Over the past couple of years, exciting data have emerged from several research groups demonstrating the importance of FAK inhibition in the i... 
Printer Friendly Version
01/06/16Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination with Merck’s Pembrolizumab and Gemcitabine in Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--Jan. 6, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem’s FAK inhibitor VS-6063 in combination with Merck’s PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer. This is the first of several combination clinical trials the Company expects ... 
Printer Friendly Version
11/09/15Verastem Reports Third Quarter 2015 Financial and Corporate Results
BOSTON--(BUSINESS WIRE)--Nov. 9, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the third quarter ended September 30, 2015, and also provided an overview of certain corporate developments. “Our mission is to improve survival and the quality of life for patients battling cancer through the combination of our c... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.